Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley J Goldsmith

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
The Journal of Urology|November 12, 2003
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigenDavid M Nanus, Matthew I Milowsky, Lale Kostakoglu, et al.
Current Radiopharmaceuticals|March 16, 2015
Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal AntibodyShankar Vallabhajosula, Anastasia Nikolopoulou, Yuliya S Jhanwar, et al.
Leukemia & Lymphoma|March 11, 2015
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomasPeter Martin, Richard R Furman, Sarah Rutherford, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2005
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigenShankar Vallabhajosula, Stanley J Goldsmith, Klaus A Hamacher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2007
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumorsMatthew I Milowsky, David M Nanus, Lale Kostakoglu, et al.
Radiology|January 30, 2008
Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse modelRobert M Sharkey, Habibe Karacay, Shankar Vallabhajosula, et al.
Seminars in Urologic Oncology|September 7, 2002
The utility of monoclonal antibodies in the imaging of prostate cancerDaniel Yao, Edouard J Trabulsi, Lale Kostakoglu, et al.
Cancer|October 26, 2006
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin diseaseLale Kostakoglu, Stanley J Goldsmith, John P Leonard, et al.
Cancer|February 4, 2010
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancerScott T Tagawa, Himisha Beltran, Shankar Vallabhajosula, et al.
Frontiers in Oncology|August 30, 2013
Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancerScott T Tagawa, Naveed H Akhtar, Anastasia Nikolopoulou, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
The Journal of Urology|November 12, 2003
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigenDavid M Nanus, Matthew I Milowsky, Lale Kostakoglu, et al.
Current Radiopharmaceuticals|March 16, 2015
Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal AntibodyShankar Vallabhajosula, Anastasia Nikolopoulou, Yuliya S Jhanwar, et al.
Leukemia & Lymphoma|March 11, 2015
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomasPeter Martin, Richard R Furman, Sarah Rutherford, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2005
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigenShankar Vallabhajosula, Stanley J Goldsmith, Klaus A Hamacher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2007
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumorsMatthew I Milowsky, David M Nanus, Lale Kostakoglu, et al.
Radiology|January 30, 2008
Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse modelRobert M Sharkey, Habibe Karacay, Shankar Vallabhajosula, et al.
Seminars in Urologic Oncology|September 7, 2002
The utility of monoclonal antibodies in the imaging of prostate cancerDaniel Yao, Edouard J Trabulsi, Lale Kostakoglu, et al.
Cancer|October 26, 2006
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin diseaseLale Kostakoglu, Stanley J Goldsmith, John P Leonard, et al.
Cancer|February 4, 2010
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancerScott T Tagawa, Himisha Beltran, Shankar Vallabhajosula, et al.
Frontiers in Oncology|August 30, 2013
Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancerScott T Tagawa, Naveed H Akhtar, Anastasia Nikolopoulou, et al.
Pageof 7